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Background: Adipose tissue functions as an endocrine organ by releasing adipokines which 
have important roles in the regulation of inflammation and insulin sensitivity. Although there 
is evidence of improvement in circulating levels of adipokines with weight loss, few studies 
relate such changes to specific diets. We investigated the effects of weight loss achieved by two 
different diets on circulating adipokine levels in obese individuals.
Methods: A total of 120 obese patients (body mass index $ 35 kg/m2) underwent a three-month 
screening period on a low-fat, reduced-calorie diet. Patients failing to achieve a 5% weight 
loss using this approach were randomly allocated to either a low carbohydrate/high protein 
diet (n = 17) or to a commercial very low calorie diet (LighterLife®, n = 14) for a period of 
nine months.
Results: At nine months, a significant weight loss was only maintained for Lighter-
Life® (−32.3 ± 22.7 kg, P , 0.0001) but not on the low carbohydrate/high protein diet. 
Changes in adiponectin (15.8 ± 17.1 ng/mL versus −0.8 ± 6.2 ng/mL, P = 0.003) and leptin 
(−17.6 ± 24.3 ng/mL versus −3.0 ± 9.2 ng/mL, P = 0.049) at nine months were significantly 
greater for LighterLife® than for the low carbohydrate/high protein diet, which may reflect 
greater weight loss and decrease in fat mass. Changes in tumor necrosis factor-alpha, inter-
leukin-6, and plasminogen activator inhibitor type 1 did not differ significantly between the 
dietary interventions at nine months.
Conclusion: A significant weight loss of 23.8% from baseline weight was observed using a 
very low calorie diet and resulted in significant improvements in circulating levels of leptin, 
plasminogen activator inhibitor type 1, and adiponectin, which are likely to be due to weight 
loss and not macronutrient intake.
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Introduction
It is now evident that adipose tissue not only stores excess triacylglycerols, but 
  functions as an endocrine organ by releasing adipokines, which have important roles 
in the regulation of appetite, glucose and lipid metabolism, inflammation, and insulin 
resistance.1,2 Such adipokines include adiponectin, leptin, resistin, tumor necrosis 
factor (TNF)-α, plasminogen activator inhibitor-1 (PAI-1), and interleukin (IL)-6. 
TNF-α, PAI-1, and IL-6 are all proinflammatory cytokines, although IL-6 can further 
exert an anti-inflammatory action.1 It has also been observed that leptin, resistin, and 
TNF-α impair insulin sensitivity and trigger atherogenesis.1 These adipokines usu-
ally increase with adiposity and can have a detrimental role on an individual’s health. 
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antiatherogenic properties and is found to decrease with 
increased adiposity.1,2
Several studies provide evidence of improvement in 
adipokine profiles with weight loss.3–6 However, it remains 
unclear as to whether changes in the circulating adipokines 
investigated to date contribute significantly to the beneficial 
effects on health associated with weight loss.7 The extent 
of weight loss required to elicit such changes in adipokine 
levels remains unclear. In addition, the method by which 
the weight loss is achieved may also influence the adipokine 
response. Varady et al8 suggest that a minimum weight loss 
of 5% is required to have an effect on levels of key adipok-
ines (adiponectin, leptin, and resistin), but this differs from 
other studies which report the need for a 10% weight loss for 
modification in levels of some adipokines (eg, adiponectin) 
and that this varies with the degree of obesity.9
Further studies are needed to clarify the relationship 
between changes in adipokine levels and the health benefits of 
weight loss, and whether specific dietary manipulations have 
differential effects on such changes. We hypothesized that 
the extent of weight loss rather than the macronutrient intake 
will determine the degree of change in adipokine levels.
We aimed to investigate the effect of weight loss on 
  adipokine levels in individuals receiving a low carbohydrate/
high protein (LCHP) diet compared with a very low calorie 
diet (LighterLife® [LL]) diet.
Methods 
The present analysis is an ancillary study to that previously 
presented by Rolland et al10 where the methods were described. 
Dropouts were not included in this analysis because the goal 
was to evaluate the effect of diet on   adipokine levels and not 
an intention-to-treat clinical trial. In brief, patients referred 
to a specialist obesity clinic were entered into a randomized 
controlled clinical trial of differing dietary interventions 
in the management of obesity. Men and women older than 
18 years of age and a body mass index (BMI) $ 35 kg/m2 were 
included. Patients with a history of hepatic or renal disease, 
cancer, current pregnancy/lactation, on antidepressant or 
antiobesity medication, or eating disorders were excluded. All 
patients who fulfilled these criteria were invited to take part 
in this research. The study included a three-month screening 
period where patients were assigned to a 600 calorie-deficient 
diet (CDD) aiming to achieve a 5% weight loss. This was done 
to select patients who would not respond to a low-fat, reduced-
energy approach and randomly assign them to a LCHP or a 
LL diet in the form of a continuous method approach. Those 
who lost .5% of their body weight were maintained on 
this approach for an additional three months. If weight loss 
was .10% at this time, the CDD was continued for an addi-
tional six months. Completer data for this group were limited 
(n = 4) and therefore were not included in this paper.
Those patients who failed to achieve the weight loss tar-
gets were randomly allocated to either a LCHP or LL diet, 
and continued on the assigned diet for an additional nine 
months (Figure 1). Patients on CDD who achieved a 5% 
weight loss at screening but did not achieve the 10% weight 
loss three months following screening were randomized to 
the LL or the LCHP diet but their data were omitted from 
this analysis. All patients provided written informed consent. 
The study was approved by the North of Scotland Research 
Ethics Service.
Dietary intervention
Using the Schofield and the Harris Benedict equations, 
600 kcal were removed from the patients’ estimated daily 
energy intake. The amount of energy allowed was broken 
down into portions from the different food groups.10 Portion 
sizes were explained to the patients and written information 
was also provided. Patients were reviewed at weeks 2, 4, 8, 
and 12 when they were weighed, their weight loss progress 
was discussed, and they were provided with dietary advice.
Randomization and diet allocation
Patients randomized to the low LCHP diet were restricted 
to #40 g of carbohydrate per day. The energy intake was 
254 patients
contacted 
120 patients 
assigned to CDD for
3-months 
18 achieved 5% weight loss
72 randomized
34 allocated to LL
for 9 months 
38 allocated to LCHP
for 9 months
20 dropped out
14 included in
analysis
17 included in
analysis
21 dropped out
18 kept on CDD
10 achieved 10%
weight loss at 3-months
post-screening
4 remained on CDD
at 9 months
30 dropped out
90 patients screened at 
end of 3-months
Figure 1 Flow chart for patient recruitment and attrition rate. 
Abbreviations: cDD, 600 kcal-deficient diet; LL, LighterLife®; LCHP, low-carbo-
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800–1500 kcal where an 800 kcal diet was composed of 
20% carbohydrate, 40% protein, and 40% fat. Patients were 
given a booklet with information about which foods to eat 
and which to avoid. Examples of recipes were also provided. 
The diet was supplemented with multivitamins and minerals 
(Forceval®, Alliance Pharmaceuticals, Chippenham, UK).
The LL diet used in this study is administered in the form 
of soups, shakes, and bars to replace conventional food and 
provides a daily average of 550 kcal (36% carbohydrate, 
36% protein, 28% fat, and at least 100% of the recom-
mended daily allowance for all micronutrients). Patients on 
LL were advised to remain adequately hydrated while on the 
diet. LL has two distinctive stages, ie, weight loss and food 
reintroduction. During each stage, patients attend weekly 
single-sex group meetings of 7–12 people for behavior 
change therapy based on cognitive behavior therapy and 
transactional analysis methodology delivered by a trained 
LL advisor. Patients were required to remain on the weight 
loss phase for a minimum of three months, after which they 
were given a choice to continue for up to another six months 
or were assigned to the food reintroduction phase. On aver-
age, patients who completed the study remained on the diet 
for 6.9 (range 4–9) months. For the food reintroduction 
phase, solid foods were reintroduced over a 12-week period 
where patients were slowly weaned off food packs while still 
receiving advice and support. All patients came monthly to 
the trial center to be weighed for the first three months and 
then every alternate month after screening, resulting in six 
visits in nine months. Additional support was provided via 
telephone and email.
Data collection
Fat mass and fat free mass was estimated using bioelectri-
cal impedance (Tanita BC-418 MA, [Tanita Corporation, 
  Arlington Heights, IL]). Body composition and waist circumfer-
ence were measured prescreening, at screening, and at months 
3 and 9 after screening. Blood samples were obtained after an 
overnight fast prescreening, at screening, and at months 3 and 
9 after screening to measure fasting plasma glucose, insulin, 
and adipokines, including leptin, resistin, adiponectin, PAI-1 
(active), IL-6, and TNF-α. Serum samples for adipokines and 
insulin were measured in duplicate with commercially avail-
able immunoassay kits from Millipore using the Lincoplex 
system (St Charles, MO). The protocol for measurement of 
insulin and all the adipokines was carried out as described by 
the manufacturer. The sensitivities are described in Table 1. 
Intra-assay variations were 1.4%–7.9% of the coefficient 
of variation. High-density lipoprotein cholesterol (HDL), 
  triacylglycerol, and fasting glucose were analyzed in the 
Department of Clinical Biochemistry at NHS Grampian. 
Insulin resistance using fasting glucose and insulin values 
was calculated using the homeostasis model of assessment of 
insulin resistance (HOMA-IR) where HOMA-IR = [insulin]
[glucose]/22.5.
Statistical analysis
All variables were assessed for normality using the 
  Kolmogorov-Smirnov test. Any skewed data were log-
  transformed and subsequently assessed using parametric 
tests. For within group analysis, a paired t-test was used. For 
between-group analysis of changes, independent t-tests were 
used. The   Pearson correlation was used to assess the relation-
ship between changes in adipokines and changes in other con-
tinuous measurements. A Chi-squared test was used to assess 
differences for dichotomous variables. Statistical tests were 
carried out using the SPSS 15.0 for Windows software pro-
gram (SPSS Inc, Chicago, IL). Because this is an ancillary 
analysis following on from a previously published study,10 
the power for this analysis was carried out based on weight 
loss. A P value of ,0.05 (two-tailed) was considered sta-
tistically significant. Based on the mean change (31.0 kg) 
and standard deviation (16.4 kg) for weight loss observed at 
nine months,10 14 patients in each group resulted in a .99% 
power for weight change.
Results
Data are presented as means ± standard deviation, and 
changes are expressed as the mean difference changes from 
baseline ± standard deviation. Baseline characteristics are 
listed in Table 2. A total of 31 (14 in LL, 17 in LCHP) 
patients completed the study. There were significantly 
more men in the LL than the LCHP group (n = 5 and n = 1, 
respectively).
Weight, BMI, and fat free mass were significantly 
greater in the LL group than in the LCHP group (Table 2). 
When investigating the whole group, significant associa-
tions were observed between adiponectin, HDL, and PAI-1. 
Table 1 Assay sensitivities for the measured adipokines
Adipokine Sensitivity (pg/mL)
Adiponectin 145.4
insulin 50.9
interleukin-6 1.6
Leptin 85.4
Plasminogen activator inhibitor type 1 (active) 1.3
Resistin 4.5
Tumor necrosis factor-alpha 0.14Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2011:4 submit your manuscript | www.dovepress.com
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nine-month data
At nine months, the percentage weight change for the LCHP 
group was −1.4% ± 1.0% and for LL was −23.8% ± 4.0% 
(P , 0.0001). In the LL group, weight loss, waist   circumference, 
percentage body fat, fat mass, fat free mass, leptin, PAI-1, 
fasting glucose, and triacylglycerols were still significantly 
improved compared with baseline (Table 4). In addition, sig-
nificant improvements in circulating levels of adiponectin and 
HDL were observed, but HOMA-IR was no longer significant 
(Table 4). Changes in adiponectin were inversely associated 
with changes in weight, BMI, fat mass, percentage body fat, 
waist circumference, IL-6, and TNF-α. Changes in leptin were 
associated with changes in weight, BMI, fat mass, waist cir-
cumference, fat free mass, and   percentage body fat. Changes 
in leptin were inversely associated with HDL. Changes in 
TNF-α were associated with changes in IL-6, and inversely 
associated with changes in adiponectin. Changes in PAI-1 
were associated with changes in fat mass (Table 5). There 
were no significant changes from baseline at nine months 
for the LCHP group (Table 4). However, changes in leptin 
were inversely associated with changes in HDL (r = – 0.573, 
P = 0.032). Overall, changes at nine months for weight, waist 
circumference, fat mass, adiponectin, leptin, fasting glucose, 
and HDL were significantly greater for the LL group than for 
the LCHP group (Table 4).
Discussion
In the present study, there was a significant weight loss at three 
months for patients on both LL and LCHP. However, signifi-
cant weight loss at nine months was only maintained in the LL 
group. Changes in adiponectin and leptin were significantly 
greater in the LL group than in the LCHP group which may be 
due to greater weight loss and decrease in fat mass. However, 
changes in TNF-α, IL-6, PAI-1, and resistin did not differ 
significantly between the dietary groups at nine months.
At baseline, we observed a trend for adiponectin to be 
inversely correlated with weight and BMI, but this did not 
reach statistical significance, possibly due to the small sample 
size. Surprisingly, there was no significant inverse correlation 
between adiponectin and waist circumference, which was 
unexpected because other studies have demonstrated that 
waist circumference is a good correlate for adiponectemia.12,13 
Although the sample size was small, this may not be the 
reason for the lack of correlation between adiponectin, BMI, 
and waist circumference. Mean BMI for the participants in 
the study was greater than 40 kg/m2. There is evidence to 
suggest that the incidence of metabolic syndrome decreases 
beyond a BMI of 37.5 kg/m2.14
Table 2 Baseline characteristics of the two dietary interventions
Variable LL (n = 14) LCHP (n = 17) P
Age (years) 41.9 ± 6.5 45.8 ± 13.8 0.314
Gender
Male 5 (36) 1 (6) 0.036
Female 9 (64) 16 (94)
Smokers 0 (0) 1 (6) 0.356
Weight (kg) 129.5 ± 23.9 110.1 ± 10.6 0.012
BMi (kg/m2) 46.7 ± 9.0 40.6 ± 3.7 0.031
Waist circumference (cm) 127.5 ± 17.8 123.8 ± 10.6 0.031
Fat mass (kg) 61.7 ± 18.8 52.6 ± 7.6 0.110
Fat free mass (kg) 67.8 ± 14.3 57.4 ± 8.1 0.025
Percentage body fat (%) 47.2 ± 8.4 47.8 ± 4.9 0.797
Adiponectin (ng/mL) 20.3 ± 12.5 24.7 ± 14.4 0.384
iL-6 (pg/mL) 4.4 ± 2.9 2.9 ± 2.4 0.119
Leptin (ng/mL) 42.3 ± 20.3 43.5 ± 13.8 0.860
PAi-1 (active) (ng/mL) 52.5 ± 29.7 59.4 ± 54.0 0.926
Resistin (ng/mL) 21.1 ± 7.2 21.4 ± 18.2 0.164
TnF-α (pg/mL) 4.3 ± 2.7 5.1 ± 2.0 0.549
insulin (μUi/mL) 12.3 ± 8.2 14.6 ± 6.6 0.212
Fasting glucose (mmol/L) 5.3 ± 0.8 5.3 ± 0.6 0.912
hOMA-iR 3.1 ± 2.6 3.5 ± 1.8 0.619
hDL (mmol/L) 1.3 ± 0.2 1.4 ± 0.3 0.190
Triacylglycerol (mmol/L) 1.2 ± 0.7 1.6 ± 1.2 0.178
Notes: Values are means ± standard deviation; (percentages).
Abbreviations: BMI, body mass index; HDL, high-density lipoprotein cholesterol; 
HOMA-IR,  homeostatic  model  assessment-insulin  resistance;  IL-6,  interleukin-6; 
LCHP, low carbohydrate/high protein; LL, LighterLife®; PAI-1, plasminogen activator 
inhibitor type 1; TNF-α, tumor necrosis factor alpha.
PAI-1 also had significant associations with insulin and 
HOMA-IR. Leptin was significantly associated with per-
centage body fat and TNF-α, while IL-6 was inversely 
associated with HDL (Table 3). There were no significant 
gender differences for the adipokines with the excep-
tion of leptin, for which the levels were significantly 
greater in women than in men (46.7 ± 15.5 ng/mL versus 
28.2 ± 14.6 ng/mL, P = 0.014). However, this was no 
longer significant after adjusting for percentage body fat 
(P = 0.089).
Three-month data
At three months, percentage weight loss for the LCHP 
group was −2.9% ± 4.2% and for LL was −18.4% ± 5.4% 
(P , 0.0001). Weight, waist circumference, percentage body 
fat, fat mass, leptin, PAI-1, fasting glucose, HOMA-IR, 
and triacylglycerols had improved significantly in the LL 
group (Table 4). However, HDL and fat free mass decreased 
significantly from baseline in the LL group (Table 4). A 
significant improvement from baseline to three months was 
observed for weight, percentage body fat, fat mass, insulin, 
and HOMA-IR in the LCHP group (Table 4).Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2011:4 submit your manuscript | www.dovepress.com
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Interestingly, our findings support the evidence presented 
by Plaisance et al,15 who reported that baseline adiponectin 
levels were strongly correlated with mean HDL cholesterol. 
  Association of moderately decreased risk of CVD with increased 
adiponectin is thought to be mediated in part by the effects 
of adiponectin on HDL, through parallel increases in both. 
  However, how adiponectin affects HDL remains unknown.16 In 
the LL group, changes in adiponectin were significant at nine 
months but not at three months. Weight loss increased signifi-
cantly from three to nine months in this group, which would 
suggest that a weight loss greater than 18.4% is required for 
statistically significant improvements in circulating adiponectin 
levels. Changes in adiponectin were inversely associated with 
fat mass, waist circumference, IL-6, and TNF-α at nine months, 
suggesting an improvement in inflammatory status with weight 
loss and the associated increase in adiponectin.
In the present study, leptin was significantly associated 
with percentage body fat at baseline, which is consistent 
with previous findings.17 There was no significant correlation 
found between leptin and waist circumference in the present 
study at baseline. This suggests that there may be a greater 
release of leptin from peripheral subcutaneous adipose tissue 
compared with visceral adipose tissue. Studies have shown 
that there are variations in leptin gene expression in adipose 
tissue depending on the site where it is deposited, where 
expression is greater in subcutaneous compared with visceral 
adipose tissue.18,19 Alternatively, the lack of   association 
between leptin and waist circumference may have been 
due to issues in the measurement of waist circumference in 
grade III obese patients, a difficulty which is well recognized. 
Establishing the correct location and reading the tape in situ 
can be problematic. In addition, different protocols yield 
different results.20
Leptin was significantly decreased at three and nine 
months in the LL group. The changes in leptin were sig-
nificantly associated with fat mass, percentage body fat, 
and waist circumference. This is consistent with a number 
of studies in which leptin is shown to decrease in response 
to weight loss.21–24 There was also an association between 
leptin change and waist circumference change at nine months, 
reflecting an overall loss of fat mass. In addition, despite the 
minimal weight loss for the LCHP group, changes in leptin 
were inversely associated with HDL at nine months. This 
may suggest that even a small reduction in weight results in 
a beneficial trend of improvement in leptin levels which is 
likely to improve cardiovascular risk.
Levels of PAI-1 at baseline were associated with waist 
circumference, HOMA-IR, and insulin, suggesting that PAI-1 
is involved in insulin resistance as previously reported.25 
Weight loss has been found to reduce the levels of PAI-1,26–28 
indicating the influence of adipose tissue on the levels of this 
protein. Our study data are in support of this evidence, where 
changes in PAI-1 were associated with changes in fat mass 
for the LL group at nine months.
Table 3 Baseline correlations for all study participants
Adiponectin IL-6 Leptin PAI-1 Resistin TNF-α Insulin
Weight −0.044 0.220 0.019 0.059 0.241 −0.079 0.090
BMi −0.107 0.353 0.333 0.127 0.315 0.167 0.045
Wc 0.033 0.143 −0.036 0.144 0.211 −0.124 0.379*
FM −0.033 0.320 0.309 0.150 0.326 0.124 0.061
FFM −0.069 −0.023 −0.333 −0.079 0.014 −0.277 0.074
% BF 0.084 0.256 0.478** 0.149 0.285 0.284 −0.014
Adiponectin – −0.128 0.086 −0.316 0.103 0.128 −0.289
iL-6 −0.128 – 0.220 0.109 0.056 0.252 0.231
Leptin 0.086 0.220 – 0.061 0.000 0.391* 0.257
PAi-1 −0.316 0.109 0.061 – −0.022 −0.101 0.386*
Resistin 0.103 0.056 0.000 −0.022 – −0.169 −0.099
TnF-α 0.128 0.252 0.391* −0.101 −0.169 – 0.165
insulin −0.298 0.231 0.257 0.386* -0.099 0.165 –
Fg −0.294 0.055 −0.119 0.223 0.123 0.287 0.331
hOMA −0.344 0.141 0.207 0.399* −0.049 0.212 0.979**
hDL 0.455* −0.374* 0.053 −0.263 −0.062 0.154 −0.357
TAg 0.010 −0.188 −0.272 0.249 0.058 0.052 0.023
Notes: *P , 0.05; **P , 0.01.
Abbreviations: % BF, percent body fat; BMI, body mass index; FG, fasting glucose; FM, fat mass; FFM, fat free mass; HDL, high-density lipoprotein cholesterol; HOMA, 
homeostatic model assessment; IL-6, interleukin-6; PAI-1, plasminogen activator inhibitor type 1; TAG, triacylglycerol; TNF-α, tumor necrosis factor alpha; WC, waist 
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Table 4 changes in variables between baseline and three and nine months (completers only)
Variable Baseline 3 months 9 months Change  
at 9 months
P (change between both   
studies at 9 months)
Weight (kg)
LL (n = 14) 129.5 ± 23.9 105.5 ± 20.1* 97.2 ± 20.8* −32.3 ± 22.7 ,0.0001
LchP (n = 17) 110.1 ± 10.6 107.1 ± 13.7* 108.7 ± 13.2 −1.3 ± 4.7
BMI (kg/m2)
LL 46.7 ± 9.0 38.1 ± 7.6 34.4 ± 9.2* −12.3 ± 10.0* 0.001
LchP 40.6 ± 3.6 39.5 ± 4.3 40.1 ± 4.1 −0.5 ± 1.8
Waist circumference (cm)
LL 127.5 ± 17.8 112.3 ± 17.5* 102.5 ± 10.4*† −25.0 ± 17.7 0.001
LchP 123.8 ± 10.6 121 ± 9.9 120.1 ± 10.1 −3.7 ± 8.0
Fat mass (kg)
LL 61.7 ± 18.8 43.2 ± 14.7* 34.4 ± 18.3*† −27.3 ± 19.0 ,0.0001
LchP 52.6 ± 7.6 50.3 ± 9.2* 52.1 ± 10.8 −0.5 ± 4.9
Fat free mass (kg)
LL 67.8 ± 14.3 62.4 ± 12.7* 62.7 ± 13.5* −5.1 ± 5.3 0.638
LchP 57.4 ± 8.1 56.8 ± 9.2 56.6 ± 8.4 −0.8 ± 2.8
Percentage body fat (%)
LL 47.2 ± 8.4 40.5 ± 8.7* 34.3 ± 12.9*† −12.9 ± 9.4 ,0.0001
LchP 47.8 ± 4.9 46.7 ± 5.3* 47.7 ± 6.0 −0.1 ± 2.6
Adiponectin (ng/mL)
LL 20.3 ± 12.5 22.4 ± 7.8 36.1 ± 11.1*† 15.8 ± 17.1 0.003
LchP 24.7 ± 14.4 23.9 ± 13.2 23.9 ± 13.2 −0.8 ± 6.2
IL-6 (pg/mL)
LL 4.4 ± 2.9 4.5 ± 5.3 4.4 ± 5.4 0.1 ± 4.4 0.716
LchP 2.9 ± 2.4 3.1 ± 3.8 2.5 ± 1.7 −0.4 ± 2.5
Leptin (ng/mL)
LL 42.3 ± 20.3 26.1 ± 21.8* 24.7 ± 21.1* −17.6 ± 24.3 0.049
LchP 43.5 ± 13.8 41.1 ± 17.1 40.5 ± 14.7 −3.0 ± 9.2
PAI-1 (active) (ng/mL)
LL 52.5 ± 29.7 20.2 ± 11.1* 20.5 ± 19.3* −32.0 ± 34.4 0.727
LchP 59.4 ± 54.0 50.6 ± 43.3 49.0 ± 44.9 −10.5 ± 56.2
Resistin (ng/mL)
LL 21.1 ± 7.2 17.4 ± 7.0 16.7 ± 7.6 −4.4 ± 9.5 0.720
LchP 21.4 ± 18.2 16.4 ± 11.0 16.0 ± 7.5 −5.5 ± 15.8
TNF-α (pg/mL)
LL 4.3 ± 2.7 4.1 ± 2.6 4.5 ± 2.9 0.3 ± 2.8 0.928
LchP 5.1 ± 2.0 5.1 ± 2.7 5.2 ± 2.0 0.2 ± 1.5
Insulin (μIU/mL)
LL 12.3 ± 8.2 10.6 ± 12.7 10.9 ± 7.4 −3.7 ± 7.4 0.902
LchP 14.6 ± 6.6 12.1 ± 6.5* 12.2 ± 7.3 −4.0 ± 11.1
Fasting glucose (mmol/L)
LL 5.3 ± 0.8 4.6 ± 0.5* 4.7 ± 0.3* −0.7 ± 0.9 0.034
LchP 5.3 ± 0.6 5.4 ± 0.6 5.2 ± 0.5 −0.1 ± 0.5
HOMA-IR
LL 3.1 ± 2.6 2.1 ± 2.5* 2.2 ± 1.5 −1.6 ± 2.4 0.832
LchP 3.5 ± 1.8 2.9 ± 1.6* 2.8 ± 1.8 −1.1 ± 2.7
HDL (mmol/L)
LL 1.3 ± 0.2 1.2 ± 0.1* 1.5 ± 0.2*† 0.2 ± 0.2 0.018
LchP 1.4 ± 0.3 1.4 ± 0.3 1.4 ± 0.4 0.0 ± 0.2
Triacylglycerol (mmol/L)
LL 1.2 ± 0.7 0.9 ± 0.2* 0.7 ± 0.2* −0.4 ± 0.8 0.070
LchP 1.6 ± 1.2 1.5 ± 0.9 1.4 ± 0.9 −0.2 ± 0.7
Notes: Values are means ± standard deviation. *Indicates a significant difference (P , 0.05) from baseline. †Indicates a significant difference (P , 0.05) from 3 months.
Abbreviations: BMI, body mass index; IL-6, interleukin-6; LCHP, low carbohydrate/high protein; LL, LighterLife®; PAI-1, plasminogen activator inhibitor type 1; TNF-α, 
tumor necrosis factor alpha; HOMA-IR, homeostatic model assessment-insulin resistance; HDL, high-density lipoprotein.Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2011:4 submit your manuscript | www.dovepress.com
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There was no evidence from the present study to sup-
port a strong link between resistin levels and weight. Of all 
the adipokines examined in this study, resistin appears to 
be the most controversial because the evidence appears to 
be equivocal and inconclusive.29–31 Further human studies are 
required to confirm whether there is a relationship between 
resistin and obesity, including insulin resistance and type 2 
diabetes mellitus.
Similarly, despite the fact that IL-6 has been found to be 
increased in obesity32,33 and reduced in response to weight 
loss,34 no significant differences at baseline or in response 
to diet were observed here. Subcutaneous adipose tissue 
is thought to release approximately 30% of systemic IL-6, 
and visceral adipose tissue is thought to release even more. 
However, the lack of change may be explained by the fact 
that only about 10% of total IL-6 is produced by fat cells.35
In addition, mean levels of TNF-α did not correlate sig-
nificantly with weight, waist circumference, or percentage 
body fat at baseline. These results were unexpected, because 
it is widely reported that TNF-α is linked with obesity.36 Also, 
TNF-α did not show any significant decrease in response to 
weight loss or diet. However, in a study by Arvidsson et al,37 
circulating levels of TNF-α did not show a significant dif-
ference after a mean weight loss of 7.5% at 10 weeks. These 
authors concluded that adipose tissue has only a minor effect 
on the regulation of circulating TNF-α levels. Thus, TNF-α 
seems to be produced and acts locally in human fat tissue,38 
and there is no in situ release from adipose tissue into the 
blood.35 A number of studies have observed no changes in 
IL-6 or TNF-α after significant reductions in weight (5–9 kg) 
with dietary and exercise interventions.39,40
However, it was interesting to observe that changes in 
IL-6 and TNF-α were significantly correlated at nine months 
in the LL group. This could be explained by the relationship 
between IL-6 and TNF-α whereby IL-6 exerts proinflamma-
tory activity itself and increases TNF-α.1 This would suggest 
that, despite weight loss not resulting in significant improve-
ments in circulating levels of IL-6 and TNF-α, there appears 
to be an underlying clinically significant response whereby 
reduction in weight results in a decrease in inflammation.
There is evidence that weight loss achieved using a 
very low calorie diet results in changes in adipokine levels 
similar to those observed in response to bariatric surgery. 
Mitterberger et al41 compared a group of patients for whom 
weight loss was achieved by dietary caloric restriction only 
with a group of patients in whom caloric restriction was 
induced by bariatric surgery (three gastric bypasses and eight 
gastric bands). They reported that despite the fact that only 
a 26% ± 7% weight loss was achieved in the dietary caloric 
restriction as compared with 43% ± 10% in the bariatric 
surgery group, changes in adipokines were not significantly 
different between the two groups. This may suggest an 
important role for the use of a weight loss approach, such as 
the very low calorie diet instead of bariatric surgery, which is 
Table 5 correlations for changes from baseline to nine months for the LighterLife® group
Adiponectin IL-6 Leptin PAI-1 Resistin TNF-α Insulin
Weight −0.560* 0.213 0.743** 0.505 −0.072 0.158 0.224
BMi −0.612** 0.258 0.730* 0.462 −0.147 0.265 0.126
Wc −0.578* 0.217 0.720** 0.488 −0.064 0.158 0.105
FM −0.637* 0.282 0.695** 0.558* −0.064 0.237 0.204
FFM −0.119 −0.117 0.694** 0.165 −0.081 −0.189 0.296
% BF −0.681** 0.317 0.635* 0.531 −0.007 0.241 0.209
Adiponectin – −0.868** −0.392 −0.407 −0.076 −0.740** 0.317
iL-6 −0.868** – 0.209 0.186 0.220 0.779** −0.460
Leptin −0.392 0.209 – 0.474 −0.133 0.003 0.596
PAi-1 −0.407 0.186 0.474 – −0.330 −0.193 0.544
Resistin −0.076 0.220 −0.133 −0.330 – 0.141 −0.049
TnF-α −0.740** 0.779** 0.003 −0.193 0.141 – −0.466
insulin 0.317 −0.460 0.596 0.544 −0.049 −0.466 –
Fg −0.427 0.177 0.439 0.238 −0.114 0.294 −0.115
hOMA 0.144 −0.337 0.708 0.652 −0.73 −0.349 0.917**
hDL −0.506 −0.171 −0.573* −0.508 −0.332 0.046 −0.412
TAg 0.531 0.306 0.336 0.437 0.105 0.130 0.417
Notes: *P , 0.05; **P , 0.01.
Abbreviations: % BF, percent body fat; BMI, body mass index; FG, fasting glucose; FM, fat mass; FFM, fat free mass; HDL, high-density lipoprotein cholesterol; HOMA, 
homeostatic model assessment; IL-6, interleukin-6; PAI-1, plasminogen activator inhibitor type 1; TAG, triacylglycerol; TNF-α, tumor necrosis factor alpha; WC, waist 
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highly invasive, expensive, and can lead to long-term vitamin 
and mineral deficiencies.42
Although it remains unclear as to whether the adipok-
ines investigated to date are responsible for the beneficial 
effects on health associated with weight loss, it is clear 
from this study and several others that there are important 
associations between weight loss, certain adipokines (such 
as   adiponectin), leptin levels, and cardiovascular disease 
risk. In addition, the extent of weight loss required to elicit 
the benefits as well as the effects of the method by which 
weight loss is obtained remains unknown. However, it can 
be argued that there does seem to be a minimal weight loss 
required which was not achieved here in the LCHP group 
and a maximal weight loss beyond which further improve-
ments in circulating adipokine levels are no longer observed, 
as demonstrated in the study by Mitterberg et al.41 Further 
research would include determining if there is a ceiling effect 
for adipokine change in response to weight loss. This would 
involve directly comparing adipokine changes in response to 
weight loss achieved using a very low calorie diet as com-
pared with weight loss achieved using surgical approaches.
There were several limitations to the present study. There 
were significantly more men on LL than on LCHP, but this 
may not have been too limiting because there were no sig-
nificant gender effects on adipokine when all patients were 
combined at baseline, except for leptin, but this discrepancy 
may have resulted in the significant differences between 
the two groups at baseline for weight, waist circumference, 
and fat free mass. In addition, although the sample size pro-
vided a . 99% power for weight loss, the sample sizes may 
have been too small to observe associations and changes in 
adipokines, which would have been expected based on the 
literature.
Moreover, use of the multiplexed assay has been criticized 
in the scientific literature.43 The multiplexed bead immuno-
assay allows the simultaneous detection of adipokines in 
small blood samples which may be particularly useful when 
samples are difficult to obtain. The use of this approach has 
been validated and found to be useful for leptin, adiponectin, 
and insulin in the evaluation of changes in obesity markers 
following weight reduction.43 The relationship between the 
multiplexed bead immunoassay when compared with the 
radioimmunoassay or enzyme-linked immunoassay for other 
adipokines such as resistin, IL-6, and TNF-α, were reported 
to be quite weak. These differences could be explained by 
differences in antibody pairs and sample diluents, as well as 
the low effects of low concentrations of these adipokines. In 
addition, assay sensitivity remains an issue when compared 
with ultrasensitive enzyme-linked immunoassay methods.43 
However, the ability of multiplexed assays to detect adi-
pokines of a broader dynamic range than enzyme-linked 
immunoassays, as well as its greater cost-effectiveness, time 
efficiency, requirement of smaller sample volumes, and the 
removal of interassay variability suggest that this approach 
is still to be considered a powerful tool, albeit with the above 
limitations.
Conclusion
It would appear that the significant weight loss of 23.8% 
observed on LL resulted in significant improvements in cir-
culating levels of leptin, PAI-1, and adiponectin. Changes in 
these adipokines possibly resulted in improvements in fasting 
glucose, triacylglycerols, and HDL. This is most likely due 
to the overall weight loss achieved rather than macronutrient 
intake. Further research examining the adipokine response to 
weight loss using a very low calorie diet in comparison with 
surgical interventions would be beneficial to determine if the 
adipokine response to weight loss has a ceiling effect.
Disclosure
Professor Iain Broom is the Medical Director for LighterLife 
UK Ltd, which provided the funding for this study.
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